title: Acute megakaryocytic leukemia: What have we learned.
abstract: Acute megakaryocytic leukemia (AMegL) is a biologically heterogenous subtype of acute myeloid leukemia (AML) that arises from megakaryocytes. Improvements in the accuracy of diagnosing AMegL as well as interest in the molecular analysis of leukemias have led to an increased amount of data available on this rare AML subtype. In this review, we will analyze the diverse molecular features unique to AMegL and how they have influenced the development of novel treatment strategies, including polyploidization. The review will also consider the data available on clinical outcomes in AMegL and how it is a poor individual prognostic factor for AML. Finally, the role of allogeneic hematopoietic stem cell transplant in AMegL will be explored.
authors.affiliation: Department of Internal Medicine, The University of Tennessee Health Science Center, USA. Electronic address: ahahn100@gmail.com.
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Hahn
authors.affiliation: Department of Internal Medicine, The University of Tennessee Health Science Center, USA; Department of Hematology/Oncology, The West Cancer Center, USA.
authors.forename: Bojia
authors.initials: B
authors.lastname: Li
authors.affiliation: Department of Internal Medicine, The University of Tennessee Health Science Center, USA.
authors.forename: Philippe
authors.initials: P
authors.lastname: Prouet
authors.affiliation: Department of Internal Medicine, The University of Tennessee Health Science Center, USA.
authors.forename: Smith
authors.initials: S
authors.lastname: Giri
authors.affiliation: Department of Internal Medicine, Reading Health System, USA.
authors.forename: Ranjan
authors.initials: R
authors.lastname: Pathak
authors.affiliation: Department of Hematology/Oncology, The West Cancer Center, USA.
authors.forename: Mike G
authors.initials: MG
authors.lastname: Martin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D064096:Aurora Kinase A / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D001381:Azepines / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002893:Chromosomes, Human, Pair 3; D050676:Core Binding Factor Alpha 2 Subunit / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D050982:GATA1 Transcription Factor / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007947:Leukemia, Megakaryoblastic, Acute / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008533:Megakaryocytes / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014635:Valproic Acid / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001381:Azepines; D050676:Core Binding Factor Alpha 2 Subunit; D050982:GATA1 Transcription Factor; C494688:GATA1 protein, human; C550258:MLN 8237; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C493728:RUNX1 protein, human; D014635:Valproic Acid; C576917:AURKA protein, human; D064096:Aurora Kinase A
keywords: AML M7; Acute megakaryocytic leukemia; Allogeneic hematopoietic stem cell transplant; Clinical outcomes; Molecular features; Novel therapies; Polyploidization